The document discusses survey results from clinical investigators and practicing oncologists on their use of adjuvant chemotherapy regimens for breast cancer patients. The most common regimens used were anthracycline-containing regimens like AC for node-negative patients and TAC for node-positive patients. More clinicians were using taxane-containing regimens like AC followed by paclitaxel or docetaxel-cyclophosphamide over time. Many clinicians had information on or used gene expression assays like Oncotype DX or MammaPrint to guide chemotherapy decisions.

1. Patterns of Care in Medical Oncology Adjuvant Chemotherapy

2. In general, when using chemotherapy in the adjuvant setting for patients with smaller, node-negative , HER2-negative tumors, what tends to be the most common regimen you use? * 14% of CIs use dose-dense AC 2007 2006 10% 8% Other Clinical investigators (CI) 4% 6% 41%* 39% 9% CMF 7% 60% 16% AC/taxane regimens AC TC

3. In general, when using chemotherapy in the adjuvant setting for patients with smaller, node-negative , HER2-negative tumors, what tends to be the most common regimen you use? * 9% of POs use dose-dense AC 2007 2006 2% 9% Other Practicing oncologists (PO) 5% 20% 52%* 21% 4% CMF 19% 65% 3% AC/taxane regimens AC TC

4. In general, when using chemotherapy in the adjuvant setting for patients with node-positive , HER2-negative tumors, what tends to be the most common chemotherapy regimen you use? 2007 2006 Clinical investigators (CI) 17% 9% Other 0% 20% 0% 63% 4% AC  docetaxel q3wk 16% 0% 71% TAC AC  paclitaxel q3wk Dose-dense AC  paclitaxel q2wk

5. In general, when using chemotherapy in the adjuvant setting for patients with node-positive , HER2-negative tumors, what tends to be the most common chemotherapy regimen you use? 2007 2006 20% 6% Other Practicing oncologists (PO) 7% 12% 7% 54% 10% AC  docetaxel q3wk 13% 20% 51% TAC AC  paclitaxel q3wk Dose-dense AC  paclitaxel q2wk

6. What percent of your patients with node-negative breast cancer who receive adjuvant chemotherapy receive regimens that include taxanes? 2007 2006 2005 44% 38% 28% Mean Practicing oncologists (PO) Clinical investigators (CI) 58% 32% 40% Mean

7. Where have you received information about TC as reported by the US Oncology Group? (May have more than one response)* * All participants other than 2 POs had heard about the study. 25% 6% Reading another journal or print piece 20% 27% 73% 84% 21% Other live or enduring continuing education programs 39% 61% 18% Listening to audio interviews or roundtable discussions in the Breast Cancer Update series Reading the Journal of Clinical Oncology Attending the 2005 San Antonio Breast Cancer Symposium Clinical investigators Practicing oncologists

8. Have you utilized the adjuvant TC regimen? 2007 2006 55% 23% Percent answering yes Practicing oncologists (PO) Clinical investigators (CI) 76% 55% Percent answering yes

9. How would you compare TC (docetaxel/cyclophosphamide) to AC? Antitumor efficacy 2007 CI n = 50 2007 2006 0% 0% AC is significantly more efficacious Clinical investigators (CI) 0% 22% 62% 16% 0% AC is somewhat more efficacious 23% 66% 11% Both are similar in efficacy TC is somewhat more efficacious TC is significantly more efficacious

10. How would you compare TC (docetaxel/cyclophosphamide) to AC? Antitumor efficacy 2007 PO n = 135 2007 2006 1% 0% AC is significantly more efficacious Practicing oncologists (PO) 5% 64% 27% 3% 4% AC is somewhat more efficacious 43% 42% 11% Both are similar in efficacy TC is somewhat more efficacious TC is significantly more efficacious

11. How would you compare TC (docetaxel/cyclophosphamide) to AC? Safety and tolerability 2007 2006 2% 0% AC has significantly better safety and tolerability Clinical investigators (CI) 10% 29% 51% 8% 19% AC has somewhat better safety and tolerability 36% 40% 5% Both are similar in safety and tolerability TC has somewhat better safety and tolerability TC has significantly better safety and tolerability

12. How would you compare TC (docetaxel/cyclophosphamide) to AC? Safety and tolerability 2007 PO n = 140 2007 2006 1% 1% AC has significantly better safety and tolerability Practicing oncologists (PO) 8% 32% 48% 11% 7% AC has somewhat better safety and tolerability 36% 49% 7% Both are similar in safety and tolerability TC has somewhat better safety and tolerability TC has significantly better safety and tolerability

13. Have you ordered the Onco type DX™ assay? If yes, for how many patients? 2007 2006 2005 75% 48% 34% Percent answering yes Practicing oncologists (PO) Clinical investigators (CI) 98% 80% 96% Percent answering yes 2007 2006 2005 14 10 5 Mean Practicing oncologists (PO) Clinical investigators (CI) 27 8 15 Mean

14. When the Onco type DX assay is requested for your patients, who generally initiates the order? 4% 4% 92% 6% 4% 90% Other/do not use Surgeon Medical oncologist Clinical investigators Practicing oncologists

15. If you had breast cancer and were diagnosed with a 2-cm, ER-positive, node-negative tumor with an Onco type DX recurrence score in the intermediate range, how comfortable would you be participating in the TAILORx study, in which you would be randomly assigned to hormonal therapy with or without chemotherapy? 12% 10% Very uncomfortable 19% 12% Somewhat uncomfortable 6% 24% 48% 18% 30% 21% Neutral Somewhat comfortable Very comfortable Clinical investigators Practicing oncologists

16. Are you aware of the MammaPrint ® assay? 100% 49% Percent answering yes Clinical investigators Practicing oncologists